I. Introduction: The Patent-Disclosure Tension in Agricultural Biotechnology
Agricultural biotechnology sits at an unusual intersection of public and private law. On one hand, seed companies and research institutions invest billions in developing transgenic traits, gene-edited varieties and novel germplasm. On the other hand, the United States Department of Agriculture (USDA) has, for decades, administered robust disclosure systems that deposit detailed genetic and phenotypic information about plant varieties into the public domain – often years or decades before a contested patent’s priority date.
This tension has given rise to an important but underutilized invalidity argument: that prior USDA disclosures, including Plant Variety Protection (PVP) certificate applications, the Germplasm Resources Information Network (GRIN), National Plant Germplasm System (NPGS) accession records and USDA-funded research publications, anticipate or render obvious the claimed inventions in agricultural biotech patents.
The consequences are significant. If a patentee claims a novel trait, gene sequence, or breeding method that was already disclosed through federal administrative processes – even if not framed as a “patent-style” disclosure – the claim may be invalidated on prior art grounds. Patent challengers, including generic seed producers, public-interest litigants and competing agribusinesses, have increasing incentive to mine these federal databases as litigation tools.
II. The Statutory Framework: Prior Art Under 35 U.S.C. §§ 102 and 103
A. The America Invents Act and Prior Art Redefined
The Leahy-Smith America Invents Act (AIA) of 2011 substantially revised the prior art framework applicable to patents with effective filing dates on or after March 16, 2013. Under AIA § 102(a)(1), a patent claim is anticipated if the claimed invention was “patented, described in a printed publication, or in public use, on sale, or otherwise available to the public” before the effective filing date.
The phrase “otherwise available to the public” is particularly consequential in the agricultural context. Courts and the USPTO have interpreted this broadly to encompass any publicly accessible disclosure, regardless of format or medium – including federal databases, administrative records and government-maintained germplasm repositories.
B. Pre-AIA Prior Art and Its Continued Relevance
For patents with priority dates before March 16, 2013, the pre-AIA § 102 framework governs. Under pre-AIA § 102(b), a patent is invalid if the claimed invention was “described in a printed publication in this or a foreign country” more than one year before the application date. The definition of “printed publication” under pre-AIA law was expansive: courts have held that publicly indexed catalogs, government accession lists and even conference posters can qualify if a person of ordinary skill in the art could locate them with reasonable diligence.
Given that many foundational agricultural biotech patents were filed in the 1990s and early 2000s – and litigation over them continues – pre-AIA frameworks remain highly relevant.
C. Obviousness Under § 103
Even where a single prior art reference does not fully anticipate a claim, a combination of USDA disclosures – for instance, a PVP certificate disclosing a parent variety’s traits combined with a published USDA technical bulletin describing a genetic modification technique – may render the claimed invention obvious. The KSR International Co. v. Teleflex Inc. (2007) standard’s emphasis on combining known elements using known methods applies forcefully in plant breeding, where the “person of ordinary skill” is an experienced plant geneticist with familiarity with federal germplasm systems.
III. The USDA Disclosure Ecosystem as Prior Art
A. The Plant Variety Protection Act and PVP Certificates
The Plant Variety Protection Act of 1970 (PVPA), 7 U.S.C. §§ 2321 et seq., established a sui generis intellectual property system for sexually reproduced plant varieties distinct from utility patents. To obtain a PVP certificate, an applicant must submit a detailed “variety description” disclosing the variety’s genetic lineage, morphological characteristics, agronomic performance data and distinguishing traits relative to known varieties.
Critically, these applications – including the detailed variety descriptions – are placed on public file. The USDA’s Plant Variety Protection Office (PVPO) maintains a publicly searchable database of certificates and pending applications. For patent invalidity purposes, a PVP application or certificate can constitute prior art if:
- It was publicly available before the patent’s priority date;
- It discloses the same genetic traits, sequences, or phenotypic characteristics claimed in the patent; and
- A person of ordinary skill could have located it through a reasonably diligent search.
Courts have noted that PVPA certificates occupy an unusual dual role: they are simultaneously a form of intellectual property protection and a public disclosure that seeds the prior art landscape.
B. The National Plant Germplasm System and GRIN
The NPGS, coordinated by the USDA Agricultural Research Service (ARS), maintains a collection of over 600,000 plant accessions held at various Plant Introduction (PI) stations nationwide. Corresponding records are publicly accessible through the Germplasm Resources Information Network (GRIN), an online database that indexes accession numbers, collection dates, geographic origins, genetic characterizations and phenotypic data for each preserved sample.
GRIN records have significant prior art potential because:
- Many accessions were collected and characterized decades before contested patents were filed;
- GRIN records are publicly searchable, satisfying the accessibility requirement for prior art;
- Genetic data associated with accessions – including molecular marker profiles deposited after modern characterization – can be linked to specific trait claims in patents; and
- Physical access to the underlying germplasm (available to researchers and breeders on request) further substantiates that the material and its associated information, was in the public domain.
In several post-grant proceedings before the Patent Trial and Appeal Board (PTAB), challengers have introduced GRIN accession records as prior art references against trait-specific claims, with mixed but growing success.
C. USDA Technical Bulletins, Circulars and Research Publications
The USDA publishes an extensive body of research literature through ARS, the Economic Research Service (ERS), the National Institute of Food and Agriculture (NIFA) and land-grant university cooperative extension systems. Technical bulletins, ARS research reports and NIFA-funded journal articles routinely disclose breeding methodologies, genetic transformation protocols and novel trait characterizations – sometimes years before private parties file patent applications on substantially identical subject matter.
These publications qualify as “printed publications” under both AIA and pre-AIA frameworks, provided they were publicly distributed or indexed before the patent’s effective date. The critical inquiry is whether the reference was “accessible to the public interested in the art” – a standard met by any USDA publication deposited in an indexed federal depository library or posted to a public government website.
D. Field Crop Variety Trial Data and USDA Statistical Publications
The USDA’s National Agricultural Statistics Service (NASS) and land-grant university variety trial programs annually publish extensive performance data for commercial and experimental varieties. These publications often disclose, in agronomic terms, the same yield, stress tolerance, pest resistance, or quality characteristics that are later claimed as novel inventions in biotech patents.
While agronomic performance data alone does not typically disclose the genetic mechanism underlying a trait, it can be powerful in obviousness combinations: pairing variety trial data showing that a trait was known and desirable with technical literature describing available transformation methods can establish that a skilled artisan would have been motivated to combine the elements and had a reasonable expectation of success.
IV. Evidentiary and Strategic Considerations in Litigation
A. Establishing Accessibility and Indexing
The central evidentiary challenge in deploying USDA disclosures as prior art is establishing that the reference was, in fact, publicly accessible before the patent’s priority date. For GRIN records, this may require expert testimony explaining the database’s architecture, indexing history and public accessibility timeline. For PVP certificates, the PVPO’s internal records of public file availability are generally sufficient, but counsel should confirm the specific date the application became publicly accessible rather than the certificate issuance date.
For older USDA technical bulletins and field trial reports, establishing prior availability may require evidence from federal depository library records, NTIS (National Technical Information Service) accession dates, or archived government website records preserved through the Internet Archive’s Wayback Machine.
B. Claim Mapping to USDA Disclosures
Once a potentially invalidating USDA reference is identified, patent challengers must carefully map the claim elements to the disclosure. Agricultural biotech claims frequently involve multiple layers: a specific DNA sequence, a regulatory element, a transformation method, a host plant genotype and a resulting phenotypic characteristic. A USDA germplasm record may disclose the phenotype and genotype but not the specific transformation method – requiring a combination argument under § 103.
Claim mapping in plant biotechnology is technically demanding and typically requires expert witnesses with training in molecular genetics, plant breeding and the specific crop system at issue. Experts should be prepared to explain to a lay tribunal (whether a district court jury, a PTAB panel, or a licensing arbitrator) why a GRIN accession number or a PVP variety description corresponds to a specific patent claim element.
C. Inter Partes Review and Post-Grant Proceedings
The AIA’s inter partes review (IPR) and post-grant review (PGR) proceedings at the PTAB have become a primary venue for agricultural biotech patent challenges. USDA database records and PVP certificates are well-suited to these proceedings for several reasons:
- IPR petitions must be based on patents or printed publications and USDA disclosures generally qualify as printed publications if publicly indexed;
- PTAB panels include technically trained administrative patent judges who are better equipped than general juries to evaluate complex plant genetics prior art; and
- The cost of PTAB proceedings, while significant, is typically lower than full district court litigation, making IPR a realistic option for smaller challengers.
Patent owners facing PTAB challenges based on USDA prior art will typically argue narrow claim construction to distinguish the prior art disclosure, or introduce evidence of long-felt need, industry praise and commercial success to support non-obviousness. Challengers should anticipate and rebut these secondary considerations with evidence that the trait was previously known, that skilled artisans were actively working in the relevant area and that the commercial success is attributable to market factors rather than the patented invention.
D. The “Enablement” Intersection
An important subsidiary argument arises when USDA germplasm records not only disclose the prior existence of a trait but also confirm that the physical biological material was publicly available before the patent’s priority date. If the patentee cannot show that their claimed invention was something more than a re-description of publicly deposited germplasm, the patent may face invalidity not only on prior art grounds but also on written description and enablement grounds – since the specification must demonstrate that the inventors actually possessed the invention and enabled others to practice it without undue experimentation.
V. Landmark Cases and PTAB Proceedings
A. J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc. (2001)
While this Supreme Court decision addressed the threshold question of whether utility patents could cover plants (holding that they could, alongside PVPA certificates), it implicitly set the stage for later invalidity challenges by confirming that the PVPA disclosure regime creates public-domain information. The Court’s acknowledgment that PVPA certificates require public deposit of seeds and variety descriptions has since been leveraged in invalidity arguments asserting that PVPA applicants effectively disclosed prior art.
B. Monsanto and the Roundup Ready Patent Litigation
The extensive litigation surrounding Monsanto’s Roundup Ready (glyphosate-tolerance) and Bt (insect resistance) trait patents generated a body of judicial decisions and PTAB proceedings examining whether earlier USDA-funded research on herbicide tolerance genes and Bacillus thuringiensis crystal proteins constituted invalidating prior art. While Monsanto largely prevailed in maintaining its core patents, the proceedings highlighted the importance of carefully distinguishing between government-funded research disclosures (which enter the public domain) and the specific applications claimed in subsequent patents.
C. Bowman v. Monsanto Co. (2013)
Though primarily a patent exhaustion case, Bowman generated amicus briefing and lower court arguments touching on the nature of publicly available germplasm and the scope of protection for self-replicating technologies. The case illuminated the tension between agricultural patent protection and the public availability of biological material – a tension that underlies USDA prior art arguments.
VI. Policy Dimensions and Reform Considerations
A. The Public Investment Problem
Much of the foundational research underlying agricultural biotechnology – gene sequencing, transformation protocols, trait identification – was funded by federal grants through NIFA, NSF and NIH. When the fruits of publicly funded research are disclosed through government channels and then later patented by private parties (or when private patents claim subject matter that government research had already made available), serious questions arise about the proper scope of patent protection.
The Bayh-Dole Act of 1980 governs federal ownership rights in inventions arising from federally funded research, but it does not directly resolve the prior art problem when government disclosures precede a private patent application. Reform advocates have argued for stronger mandatory disclosure requirements and clearer prior art treatment of federal research outputs.
B. Food Security and Access to Germplasm
The availability of diverse plant germplasm is foundational to global food security, particularly in the face of climate change. Overly broad agricultural biotech patents that sweep in traits and varieties already described in USDA databases can effectively restrict access to germplasm that was and should remain, in the public domain. Robust prior art challenges grounded in USDA disclosures serve not only commercial litigation interests but also the broader public interest in maintaining a rich and accessible genetic commons for plant breeding.
C. Harmonization with International Disclosure Regimes
The International Union for the Protection of New Varieties of Plants (UPOV) and the International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA) create parallel international disclosure regimes that may generate prior art under U.S. law. Foreign PVP certificates, CGIAR genebank records and FAO-maintained genetic resource databases may also support invalidity arguments in U.S. patent proceedings, particularly for varieties with international breeding histories.
VII. Practical Guidance for Patent Challengers and Holders
For Patent Challengers
- Begin prior art searches in GRIN, PVPO and USDA ARS publication databases before engaging in expensive technical expert work;
- Establish the precise public availability date of each reference through archival evidence;
- Retain experts fluent in both plant genetics and the specific USDA database systems at issue;
- In IPR petitions, frame USDA records within the AIA’s “otherwise available to the public” language and emphasize the government’s own accessibility policies;
- Combine germplasm disclosures with published methods literature to build § 103 combinations where single-reference anticipation is unavailable.
For Patent Holders
- Conduct freedom-to-operate analyses that include USDA databases before filing patent applications;
- Clearly distinguish claimed inventions from publicly deposited germplasm in the specification and prosecution history;
- Maintain detailed inventor notebooks and laboratory records establishing conception and reduction to practice dates well before any USDA-disclosed reference;
- During prosecution, proactively cite potentially relevant USDA prior art and distinguish it on the record to build prosecution history estoppel against later claim scope arguments.
VIII. Conclusion
The USDA’s vast ecosystem of public disclosures – PVP certificates, GRIN accession records, ARS technical publications and variety trial data – represents a powerful and frequently underutilized body of prior art for challenging agricultural biotechnology patents. As courts and the PTAB continue to develop doctrine around the AIA’s “otherwise available to the public” standard and as litigants grow more sophisticated in mining federal databases, these administrative disclosures will play an increasingly central role in patent validity disputes. The stakes extend well beyond individual patent disputes. Agricultural biotech patents that improperly claim subject matter already disclosed through federal systems distort the competitive landscape, restrict access to public germplasm and undermine the public investment that made the underlying science possible. Rigorous prior art challenges grounded in USDA disclosures are not merely litigation tactics – they are a mechanism for preserving the integrity of the patent system and the agricultural genetic commons on which global food security depends.